Full-Time

Scientist I/Scientist II

Medicinal Chemistry

Confirmed live in the last 24 hours

Hexagon Bio

Hexagon Bio

51-200 employees

Biotechnology firm developing medicines using genomics

Biotechnology
Healthcare

Compensation Overview

$120k - $160kAnnually

+ Bonus + Equity

Junior, Mid

Menlo Park, CA, USA

Ability to work at Menlo Park, CA laboratories.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Scientist I: Ph.D. degree in organic or medicinal chemistry
  • Scientist II: Ph.D. degree in organic or medicinal chemistry and 2 years postdoctoral or industry experience
  • Ability to perform complex multistep synthesis quickly, efficiently, and safely
  • Ability to work at Menlo Park, CA laboratories
Responsibilities
  • Design of new drug candidates
  • Multistep synthesis of new drug candidates
  • May manage aspects of a drug discovery project
  • May manage chemistry at a contract research organization

Hexagon Bio focuses on discovering and developing new medicines through synthetic biology and data science. By utilizing reduced DNA sequencing costs, the company accesses extensive genomic data from various species. Their proprietary algorithm identifies small molecule inhibitors that target specific proteins involved in diseases like cancer. Hexagon Bio's synthetic biology platform enables rapid production of lead compounds for clinical development, allowing for quicker advancement compared to traditional methods. The team consists of experts in various scientific fields, collaborating to enhance medical discovery. Targeting the pharmaceutical and healthcare sectors, Hexagon Bio aims to develop treatments for complex diseases and generates revenue through licensing drug candidates to larger pharmaceutical companies.

Company Stage

Late Stage VC

Total Funding

$178.6M

Headquarters

Menlo Park, California

Founded

2016

Growth & Insights
Headcount

6 month growth

-13%

1 year growth

-18%

2 year growth

27%
Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $77.3 million in Series B financing to expand their discovery platform.
  • Leverages reduced DNA sequencing costs to access vast genomic data for drug development.
  • Focuses on unmet medical needs, particularly in cancer treatment, with targeted therapies.

What critics are saying

  • Faces competition from biotech companies like Insitro and Recursion Pharmaceuticals.
  • Continuous updates to their platform may be costly due to rapid technological advancements.
  • Potential ethical and regulatory challenges in mining microbial genomes could delay drug approval.

What makes Hexagon Bio unique

  • Hexagon Bio uses synthetic biology to mine fungal genomes for drug discovery.
  • Their proprietary platform combines data science and synthetic biology for targeted therapeutics.
  • Hexagon Bio's team includes experts in computational biology, biochemistry, and software engineering.

Help us improve and share your feedback! Did you find this helpful?